Work

TNFR1 loss in the antigen-retaining tumor model alters inflammatory responsiveness and CAR-T-cell functional fitness

Year: 2026
Type: article
Abstract: Resistance to CAR-T-cell therapy remains a major challenge in solid tumors, where target antigen expression may be retained despite cytotoxic T-cell attack. Resistance of tumor cells to cytokine killing mediated by T-cell-secreted tumor necrosis factor (TNF) and interferon-γ (IFN-γ) may contribute to this phenotype. We investigated this possibility using a CD19 antigen-retaining tumor-cell model with differential TNFR1 status, co-cultured in vitro with CAR-T cells. CRISPR/Cas9-mediated ablation of TNFR1 in tumor cells attenuated cytokine-induced apoptotic responses. At the molecular level, TNFR1-knockout cells exhibited reduced NF-κB activation, attenuated ICAM1 induction, and diminished caspase-3/7 activity compared with WT control cells. To assess the consequences of CAR-T-cell exposure to these resistant tumor cells, CAR-T cells were analysed following both short-term and serial long-term exposure to TNFR1-knockout target cells. Although short-term assays showed no reduction in CAR-T-cell/tumor-cell conjugate formation, serial exposure to surviving TNFR1-deficient tumor cells was associated with reduced CAR-T-cell cytotoxicity upon rechallenge. These CAR-T cells also displayed lower cytokine output and altered transcriptional states. Targeted single-cell profiling identified a CXCL13-associated cycling CAR-T-cell state during tumor-cell co-culture. A transcriptional signature derived from this CAR-T state was also detectable, in an exploratory analysis, in an independently clustered repeated CD3/CD28-stimulation dataset and in publicly available immune checkpoint blockade cohorts. Taken together, our findings support the hypothesis that prolonged exposure to antigen-positive tumor cells that survive inflammatory cytokine-mediated killing may reduce subsequent CAR-T-cell functional fitness and cytotoxic potential.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,990
OpenAlex ID: W7237364326
FWCI:
Cites:
Cited by:
Related to: